Insights

Gathering insights about Vivy…

Similar companies to Vivy

Vivy Tech Stack

Vivy uses 8 technology products and services including LinkedIn Recruiter, GitHub, TYPO3, and more. Explore Vivy's tech stack below.

LinkedIn Recruiter
Applicant Tracking Systems
GitHub
Communication And Collaboration
TYPO3
Content Management System
Modernizr
Javascript Libraries
Prism
Javascript Libraries
iOS
Programming Languages
Java
Programming Languages
Spring
Web Frameworks

Media & News

Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine
NEW HAVEN, Conn., June 16, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced enrollment of participants in its Phase 3 LIBERTY clinical trial is complete. The trial is comparing the safety and tolerability of the company's investigational COVID-19 monoclonal antibody VYD2311 with an mRNA COVID-19 vaccine. The trial is also evaluating the safety and immune response when both are given together. VYD2311 is being developed as an alternative to vaccines for preventing COVID-19. The LIBERTY study is a randomized, double-blind trial involving healthy adults. A primary endpoint of the trial is to assess the side effects and tolerability of COVID antibody versus vaccine through Day six, for a total of seven days. Invivyd expects to report initial results from the study in the third quarter of 2026. These results may be released alongside data from the company's pivotal DECLARATION clinical trial.
Jun 16, 2026 | www.globenewswire.com
Invivyd doses first participants in Phase 3 COVID-19 trial
Invivyd Inc (NASDAQ:IVVD) has dosed the first participants in its LIBERTY Phase 3 trial, a study testing the company's monoclonal antibody VYD2311 for the prevention of COVID-19 against and alongside an mRNA vaccine. The randomized, double-blind trial is evaluating the safety, tolerability and immune response of VYD2311 on its own, an mRNA COVID-19 vaccine on its own, and VYD2311 given together with a COVID-19 vaccine in healthy adults, the New Haven, Connecticut-based company said.
Jun 09, 2026 | www.proactiveinvestors.com
Invivyd doses first participants in Phase 3 COVID-19 trial
Invivyd Inc (NASDAQ:IVVD) has dosed the first participants in its LIBERTY Phase 3 trial, a study testing the company's monoclonal antibody VYD2311 for the...
Jun 09, 2026 | www.proactiveinvestors.com
Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration
NEW HAVEN, Conn., June 09, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the first participants have been dosed in the LIBERTY Phase 3 clinical trial, a randomized, double-blind study that is evaluating the safety and tolerability and immunology of VYD2311 alone, an mRNA COVID-19 vaccine alone, and VYD2311 co-administered with a COVID-19 vaccine in healthy adults. VYD2311 is Invivyd's vaccine-alternative monoclonal antibody (mAb) investigational candidate for the prevention of COVID-19. Depending on study recruitment rate, Invivyd expects to report topline data from the LIBERTY trial in Q3 2026, to accompany anticipated data from the pivotal DECLARATION clinical trial.
Jun 09, 2026 | www.globenewswire.com
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HAVEN, Conn., June 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on June 1, 2026, Invivyd granted 17 newly hired non-executive employees options to purchase an aggregate of 513,500 shares of its common stock, each as a material inducement for each employee's entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.
Jun 03, 2026 | www.globenewswire.com
Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID
NEW HAVEN, Conn., June 01, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced the completion of enrollment in the DECLARATION trial evaluating VYD2311, an investigational monoclonal antibody candidate for the prevention of symptomatic COVID-19. DECLARATION is the company's Biologics License Application (BLA)-enabling, Phase 3 randomized, placebo-controlled clinical trial to evaluate VYD2311 efficacy and safety in prevention of symptomatic COVID in a broad population of participants including adults and adolescents. Top-line results continue to be expected in approximately late Q3 2026.
Jun 01, 2026 | www.globenewswire.com
Invivyd to Participate in Upcoming Investor Events
NEW HAVEN, Conn. , May 27, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that it will participate in upcoming investor events in June: 2026 Jefferies Global Healthcare Conference in New YorkFireside Chat Date and Time: Wednesday, June 3, 2026 4:55 p.
May 27, 2026 | www.globenewswire.com

Vivy's Email Address Formats

Vivy uses at least 1 format(s):

Vivy Email Formats	Example	Percentage
First@vivy.com	John@vivy.com	63%
First.Last@vivy.com	John.Doe@vivy.com	26%
Last@vivy.com	Doe@vivy.com	11%

Frequently Asked Questions

Where is Vivy's headquarters located?

Vivy's main headquarters is located at 18 Schützenstrasse Berlin, Berlin 10117 Germany. The company has employees across 2 continents, including EuropeAsia.

What is Vivy's stock symbol?

Vivy is a publicly traded company; the company's stock symbol is IVVD.

What is Vivy's official website and social media links?

Vivy's official website is vivy.com and has social profiles on LinkedIn.

What is Vivy's NAICS code?

Vivy's NAICS code is 71394 - Fitness and Recreational Sports Centers.

How many employees does Vivy have currently?

As of June 2026, Vivy has approximately 43 employees across 2 continents, including EuropeAsia. Key team members include Director Of International Business Development: F. A.Business Development & Partner Manager: P. H.Senior Frontend Engineer: D. R.. Explore Vivy's employee directory with LeadIQ.

What industry does Vivy belong to?

Vivy operates in the Wellness and Fitness Services industry.

What technology does Vivy use?

Vivy's tech stack includes LinkedIn RecruiterGitHubTYPO3ModernizrPrismiOSJavaSpring.

What is Vivy's email format?

Vivy's email format typically follows the pattern of First@vivy.com. Find more Vivy email formats with LeadIQ.

When was Vivy founded?

Vivy was founded in 2017.

Vivy

Q: What is Vivy's official website and social media links?

Vivy's official website is vivy.com. Vivy has social profiles on LinkedIn.

Q: How many employees does Vivy have currently?

Vivy has approximately 43 employees.

Q: What technology does Vivy use?

Vivy's tech stack includes Go, SQL, Kotlin, Google Hosted Libraries, Jenkins.

Q: What is Vivy's NAICS code?

Vivy's NAICS code is 71394 (Fitness and Recreational Sports Centers).

Wellness and Fitness ServicesBerlin, Germany11-50 Employees

Vivy is a wellness and fitness services company based in Berlin, Germany, headquartered at 18 Schützenstrasse, 10117. It is pursuing the development of a digital health platform designed for personalized interactions and to connect people with services that help them manage, improve, and optimize their health. The company employs 11 to 50 people and operates with an international team that is growing. Allianz backs Vivy, providing backing from a major insurer in the digital health space. Its technology stack includes Java and Spring, iOS, and TYPO3, among other tools, to support its platform.